DiaMedica Therapeutics (DMAC) Change in Receivables (2018 - 2026)
DiaMedica Therapeutics' (DMAC) quarterly Change in Receivables came in at -$57000.0 in Q2 2026, up 38.04% on a YoY basis from -$41291.3 in Q2 2025, and down 232.56% quarter-over-quarter from $43000.0 in Q1 2026.
Powered by 
Analysis
DiaMedica Therapeutics (DMAC) Change in Receivables (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics (DMAC) has reported Change in Receivables for 9 consecutive years, with -$57000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Change in Receivables rose 38.04% year-over-year to -$57000.0; the trailing twelve-month figure through Jun 2026 stood at $83000.0 (up 136.09% YoY), and the FY2025 full-year result was $22000.0, up 116.54% from the prior year.
- Change in Receivables retreated to -$57000.0 in Q2 2026 per DMAC's latest filing, from $43000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $131000.0 in Q2 2023 and bottomed at -$101000.0 in Q3 2024.
- Historically, Change in Receivables has averaged $6333.3 across 5 years, with a median of $2500.0 in 2022.
- The sharpest annual moves came in 2022 and 2025: Change in Receivables jumped 1366.67% in 2022, then plunged 1050.0% in 2025.
- Over 5 years, Change in Receivables stood at $7000.0 in 2022, then surged by 742.86% to $59000.0 in 2023, then sank by 191.53% to -$54000.0 in 2024, then soared by 96.3% to -$2000.0 in 2025, then tumbled by 2750.0% to -$57000.0 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered -$57000.0, $43000.0, and -$2000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.86 Bn | 192.87 Bn | 7.24 Bn | 1.09 Bn |
| 2 | Gilead Sciences | 179.52 Bn | 176.34 Bn | 6.22 Bn | 333.00 Mn |
| 3 | Vertex Pharmaceuticals | 131.47 Bn | 123.62 Bn | 2.84 Bn | 140.20 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 838.50 Mn |
| 5 | Argenx Se | 61.16 Bn | 55.98 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.15 Bn | 48.02 Bn | 52.00 Mn | -53.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.20 Bn | 29.89 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Biogen | 31.65 Bn | 30.37 Bn | 1.96 Bn | 269.40 Mn |
| 9 | Roivant Sciences | 29.30 Bn | 29.30 Bn | 1.16 Mn | - |
| 10 | DiaMedica Therapeutics | 346.54 Mn | 346.54 Mn | - | -57,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -57,000.00 |
| Mar 31, 2026 | 43,000.00 |
| Dec 31, 2025 | -2,000.00 |
| Sep 30, 2025 | 99,000.00 |
| Jun 30, 2025 | -92,000.00 |
| Mar 31, 2025 | 17,000.00 |
| Dec 31, 2024 | -54,000.00 |
| Sep 30, 2024 | -101,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 59,000.00 |
| Sep 30, 2023 | 122,000.00 |
| Jun 30, 2023 | 131,000.00 |
| Mar 31, 2023 | -25,000.00 |
| Dec 31, 2022 | 7,000.00 |
| Sep 30, 2022 | -13,000.00 |
| Jun 30, 2022 | -80,000.00 |
| Mar 31, 2022 | 38,000.00 |
| Dec 31, 2021 | 26,000.00 |
| Sep 30, 2021 | 88,000.00 |